Peter Lehmann
                Brave New Psychiatry (e-book)
                (= Schöne neue Psychiatrie)
              
              
              A two-volume ebook, that reveals the risks of psychiatric drugs, 
              on the market in 1996, as well as the risks of electroshocks ruthless 
              and easy to understand. With advices how to withdraw responsible. 
              
 The two-volume publication addresses primary to 
                the treated persons and their relatives und enables them a grounded 
                and independent decision: taking psychiatric drugs in spite of 
                considerable risks for the health  or better not. If already 
                a damage is done, then the proof should be made easier, that it 
                was caused by the treatment. Workers in the psychosocial system 
                can use the book as manual and work of reference.
               Antidepressants, lithium, neuroleptics, tranquilizers, 
                psychostimulants and carbamazepine are given to more and more 
                human beings  especially to women, children and the elderly  in 
                increasing doses and in combinations that have effects not to 
                calculate. Though a critical knowledge about their dangers is 
                more important than ever.
               A chapter by its own is dedicated to the potential of dependence 
                on these substances as well as to advices how to come down. 
                The 
                Author
The 
                Author
              Peter Lehmann, D. Phil. h.c. Born in 1950. Education in pedagogy. 
                Living as independent publisher and author in Berlin. In 1989, 
                co-founder of the Organisation for the Protection from Psychiatric 
                Violence, running the Runaway-house 
                Berlin. In 1991, co-founder of the European 
                Network of (ex-) Users and Survivors of Psychiatry (ENUSP); 
                from 1997-1999, Chair of ENUSP; until 2010, board member. In 2010, 
                awarded with an Honorary 
                Doctorate in acknowledgement of "exceptional scientific 
                and humanitarian contribution to the rights of the people with 
                psychiatric experience" by the School of Psychology of the 
                Aristotle University of Thessaloniki, Greece, Faculty of Philosophy. 
                In 2011, awarded the Order of Merit of the Federal Republic of 
                Germany by the President of Germany. English publications include, 
                Withdrawal 
                from Prescribed Psychotropic Drugs (edited in 2021 together 
                with Craig Newnes);  
                Coming 
                off Psychiatric Drugs: Successful Withdrawal from Neuroleptics, 
                Antidepressants, Mood Stabilizers, Ritalin and Tranquilizers 
                (edited in 2004; e-book 
                in 2025); Alternatives 
                beyond Psychiatry, edited together with Peter Stastny 
                in 2007 (e-book 
                in 2025). More about Peter 
                Lehmann
               Additional information to "Brave New 
                Psychiatry"
              Tranquilizers (alium etc.), lithium, antidepressants (Prozac 
                etc.), neuroleptics (Haldol etc.), carbamazepine (Tegretol etc.) 
                and psychostimulants (Ritalin etc.) are used more and more in 
                the psychiatric and medical system, especially in the general 
                medicine and the paediatrics. Since 1985 the trend steadily goes 
                away from tranquilizers and towards antidepressants and neuroleptics.
               In Germany, on average 70% of all psychiatric drugs are administered 
                to women, with increasing age in rising tendency. Every seventh 
                psycho-pill is swallowed by children less than twelve years old. 
                15% of all children and adolescents and 25% of all adults are 
                considered as mentally disturbed, so they are possible consumers. 
                Nothing points out that the situation outside of Germany is fundamentally 
                different.
               In general, the treated persons do not receive information about 
                the probable, the possible and the not-excludable risks. They 
                do not know, that some substances had to be withdrawn from the 
                drug-market in the one countries, but are sold without restriction 
                in the other countries, for example penfluridol (brand name: Semap) 
                as a possible carcinogen, remoxipride (Roxiam) because of blood 
                damage, and triazolam (brand names: Halcion, Hypam) in connection 
                with amnesia and black-outs. If people want to have full information 
                on the risks, which are connected with the administration of psychiatric 
                drugs and electroshocks, they have to give serious thoughts to 
                their mechanisms and effects, especially when doctors' interests 
                in full information leave much to be desired.
              "Brave New Psychiatry" consists of two volumes, 
which are enclosed particularly.
              Peter Lehmann: "Brave New Psychiatry", 
                Vol. 1: "Wie Chemie und Strom auf Geist und Psyche wirken" 
                (= "How chemistry and electricity work on mind and psyche"), 
                E-Book. See 
                full information at www.antipsychiatrieverlag.de/snp1.htm
               English 
                language order form for orders directly at Peter Lehmann Publishing 
                / German 
                language order form 
              In the centre of attention in this volume are the many and diverse 
                risks and damages in the psychic and mental system. Main topics 
                are: drug-caused emotional impoverishment, changing of the personality, 
                depression, desperation, suicide, confusion, delirium and psychotic 
                states; disturbances of the senses, memory, concentration, sleep 
                and dreams; self-trials of doctors; animal experiments. 
               In a special chapter 
Leonard Roy Frank, the US-American expert on damages of electroshocks, shows the 
negative effects (especially loss of memory) of this disputed method.
               With an extensive register and 1102 sources from all over the 
                world.
                
                Peter Lehmann: "Brave New Psychiatry", 
                Vol. 2 "Wie Psychopharmaka den Körper verändern" 
                (= "How psychiatric drugs change the body"). Ebook. 
                See 
                full information at www.antipsychiatrieverlag.de/snp2.htm 
              
               English 
                language order form for orders directly at Peter Lehmann Publishing 
                / German 
                language order form 
              In the centre of attention here are the psychiatric drugs' short-term, 
                medium-term and long-term risks and damages, which find expression 
                in the muscle and autonomic system, for example as  partly 
                life-dangerous  muscle-cramps, movement-disorders, genetic 
                damages, harms to the liver, heart and sexual-organs.
               A chapter 
by its own is dedicated to the potential of dependence on theses substances. Its 
special status is caused by the fact, that their administrators  with the 
exception of tranquilizers  deny their potential of dependence. They conceal 
possible withdrawal-symptoms, rebound-phenomenons, supersensibility-reactions 
of the receptors as well as possible irreversible drug damages and change the 
definitions into symptoms-alteration: for example chronic anxiety after long-term 
administration of antidepressants or tranquilizers, states of confusion after 
withdrawal from lithium and chronic psychosis after administration of neuroleptics. 
Prudent advices, how the risk of relapse can be reduced and how withdrawal-effects 
can be mitigated, balance this volume.
              With an extensive register, too, and 1677 sources from all over 
              the world.